Regorafenib in the Real-Life Clinical Practice: Data from the
Czech Registry

J 2017

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

KOPEČKOVÁ, Kateřina, Tomáš BÜCHLER, Zbyněk BORTLÍČEK, Karel HEJDUK, Renata CHLOUPKOVÁ et. al.

Basic information

Original name

Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry

Name in Czech

Regorafenib v reálné klinické praxi: Data z Českého registru

Authors

KOPEČKOVÁ, Kateřina (203 Czech Republic), Tomáš BÜCHLER (203 Czech Republic), Zbyněk BORTLÍČEK (203 Czech Republic, guarantor, belonging to the institution), Karel HEJDUK (203 Czech Republic, belonging to the institution), Renata CHLOUPKOVÁ (203 Czech Republic, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic), Petra POKORNÁ (203 Czech Republic), Jiří TOMÁŠEK (203 Czech Republic), Zdeněk LINKE (203 Czech Republic), Luboš PETRUŽELKA (203 Czech Republic), Igor KISS (203 Czech Republic) and Jana PRAUSOVÁ (203 Czech Republic)

Edition

Targeted Oncology, Dordrecht, Springer, 2017, 1776-2596

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.907

RIV identification code

RIV/00216224:14110/17:00095942

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s11523-016-0458-1

UT WoS

000393121700009

Keywords in English

Rheumatoid arthritis; Ultrasonography; Synovitis; Health assessment questionnaire

Abstract

V originále

Objective To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival. Patients and Methods The data of patients treated with regorafenib were extracted from the national CORECT registry. The CORECT registry is a non-interventional post-marketing database, gathering information about patients with CRC and treated with targeted agents. Twenty oncology centres in the Czech Republic contributed to this registry. Collected data included patients’ characteristics, disease history, cancer treatments, response to treatments and safety. Results A total of 148 patients treated with regorafenib in clinical practice were analysed. At regorafenib initiation, almost all patients were fully active or slightly restricted in physical activity. Regorafenib was not administered as first-line treatment in any patient. Median progression-free survival was 3.5 months and median overall survival was 9.3 months. One-year survival rate was 44.6 %. Four partial responses were observed and 51 stable diseases. Progression was observed in 66 patients (44.6 %). The main reported adverse events were skin toxicity (5.4 %) and fatigue (2.0 %). Conclusions Regorafenib is a well-established treatment for pretreated patients with mCRC, however real-life data are scarce. Our results demonstrated slightly better efficacy of regorafenib and better safety profile in patients with mCRC compared to the randomised trials.

Links

LM2015090, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

KOPEČKOVÁ, Kateřina, Tomáš BÜCHLER, Zbyněk BORTLÍČEK, Karel HEJDUK, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Petra POKORNÁ, Jiří TOMÁŠEK, Zdeněk LINKE, Luboš PETRUŽELKA, Igor KISS and Jana PRAUSOVÁ. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. Targeted Oncology. Dordrecht: Springer, 2017, vol. 12, No 1, p. 89-95. ISSN 1776-2596. Available from: https://dx.doi.org/10.1007/s11523-016-0458-1.

@article{1362726,
   author = {Kopečková, Kateřina and Büchler, Tomáš and Bortlíček, Zbyněk and Hejduk, Karel and Chloupková, Renata and Melichar, Bohuslav and Pokorná, Petra and Tomášek, Jiří and Linke, Zdeněk and Petruželka, Luboš and Kiss, Igor and Prausová, Jana},
   article_location = {Dordrecht},
   article_number = {1},
   doi = {http://dx.doi.org/10.1007/s11523-016-0458-1},
   keywords = {Rheumatoid arthritis; Ultrasonography; Synovitis; Health assessment questionnaire},
   language = {eng},
   issn = {1776-2596},
   journal = {Targeted Oncology},
   title = {Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry},
   url = {http://dx.doi.org/10.1007/s11523-016-0458-1},
   volume = {12},
   year = {2017}
}

TY  - JOUR
ID  - 1362726
AU  - Kopečková, Kateřina - Büchler, Tomáš - Bortlíček, Zbyněk - Hejduk, Karel - Chloupková, Renata - Melichar, Bohuslav - Pokorná, Petra - Tomášek, Jiří - Linke, Zdeněk - Petruželka, Luboš - Kiss, Igor - Prausová, Jana
PY  - 2017
TI  - Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry
JF  - Targeted Oncology
VL  - 12
IS  - 1
SP  - 89-95
EP  - 89-95
PB  - Springer
SN  - 17762596
KW  - Rheumatoid arthritis
KW  - Ultrasonography
KW  - Synovitis
KW  - Health assessment questionnaire
UR  - http://dx.doi.org/10.1007/s11523-016-0458-1
L2  - http://dx.doi.org/10.1007/s11523-016-0458-1
N2  - Objective To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival. Patients and Methods The data of patients treated with regorafenib were extracted from the national CORECT registry. The CORECT registry is a non-interventional post-marketing database, gathering information about patients with CRC and treated with targeted agents. Twenty oncology centres in the Czech Republic contributed to this registry. Collected data included patients’ characteristics, disease history, cancer treatments, response to treatments and safety. Results A total of 148 patients treated with regorafenib in clinical practice were analysed. At regorafenib initiation, almost all patients were fully active or slightly restricted in physical activity. Regorafenib was not administered as first-line treatment in any patient. Median progression-free survival was 3.5 months and median overall survival was 9.3 months. One-year survival rate was 44.6 %. Four partial responses were observed and 51 stable diseases. Progression was observed in 66 patients (44.6 %). The main reported adverse events were skin toxicity (5.4 %) and fatigue (2.0 %). Conclusions Regorafenib is a well-established treatment for pretreated patients with mCRC, however real-life data are scarce. Our results demonstrated slightly better efficacy of regorafenib and better safety profile in patients with mCRC compared to the randomised trials.
ER  -

KOPEČKOVÁ, Kateřina, Tomáš BÜCHLER, Zbyněk BORTLÍČEK, Karel HEJDUK, Renata CHLOUPKOVÁ, Bohuslav MELICHAR, Petra POKORNÁ, Jiří TOMÁŠEK, Zdeněk LINKE, Luboš PETRUŽELKA, Igor KISS and Jana PRAUSOVÁ. Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. \textit{Targeted Oncology}. Dordrecht: Springer, 2017, vol.~12, No~1, p.~89-95. ISSN~1776-2596. Available from: https://dx.doi.org/10.1007/s11523-016-0458-1.

Detailed Information on Publication Record